GNMX vs IBB: Grades, Fees and Holdings Compared

Corgi Genomics & Precision Medicine ETF

GNMXCCboe

iShares Biotechnology ETF

IBBANasdaq

Overlap

30.7%by weight

Expense ratio

GNMX −0.09pt a year

GNMX0.35%IBB0.44%

Avg volume · 30D

IBB 921.2×the volume

GNMX1.79KIBB1.65M

GNMX vs IBB Performance

Jul 31, 2026 – Oct 30, 2026

+28.1%GNMX+16.7%IBB

Expense ratio: GNMX 0.35%, better; IBB 0.44%
Fund size: GNMX $1M; IBB $11.5B
1Y total return: GNMX No data; IBB +36.8%
Yield (12M): GNMX No data; IBB 0.16%
Holdings: GNMX 58; IBB 243
Avg volume (30D): GNMX 1.79K sh; IBB 1.65M sh, better
NAV per share: GNMX $38.06; IBB $217.59
52W range

ETF.net Grade

Pillar letters and Scores for GNMX, IBB, with each pillar’s weight
Pillar	GNMX	IBB
Cost30% weight	A81Higher	B69
Mission25% weight	Not scored	A83
Risk15% weight	A71Higher	B69
Tradability15% weight	F17	A95Higher
Holdings10% weight	C49Higher	C45
Durability5% weight	F0	A89Higher

Rank among Biotech & Genomics funds

How we build Categories ›

Same Category. GNMX and IBB are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds

See all 17 ›

IBB ranks 3rd and GNMX 11th of 17 funds in the Biotech & Genomics Category.

Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
Rank 3AIBBiShares Biotechnology ETFScore 75
Rank 4ABBPVirtus Biotech ETFScore 74
Rank 10CIBRNiShares Neuroscience and Healthcare ETFScore 43
Rank 11CGNMXCorgi Genomics & Precision Medicine ETFScore 40
Rank 11CWDNAWisdomTree BioRevolution FundScore 40

Our read on each fund

ETF.net Research

GNMXCCorgi Genomics & Precision Medicine ETF

IBBAiShares Biotechnology ETF

In short

GNMX No data

IBB Biotech's original index fund. Since 2001 IBB has packed the whole US biotech sector, roughly 250 names, into one line item for 0.44% a year, below what the typical biotech fund charges.

Stated mandate

GNMX No data

IBB The Fund seeks to track an index composed of U.S.-listed equities focused on the biotechnology sector.

Why people hold it

GNMX No data

IBB A 2001 launch makes it one of the sector's originals, and it has grown into a multi-billion-dollar fund that trades actively.
Roughly 250 stocks, so the whole US biotech bench comes along instead of a few marquee drugmakers.
0.44% a year, set by the prospectus and below the median fee in its biotech peer group.
Sticks closely to the job in its prospectus: US-listed biotech equities, nothing exotic bolted on. That lands it in the upper half of its peer group.ishares.com

Worth knowing

GNMX No data

IBB Cheaper seats exist in the same aisle: IBBQ at 0.19%, BBP at 0.34%, XBI at 0.35%.
One industry carries the whole fund. Trial readouts, FDA decisions and patent expiries drive it, with no other sector to cushion a rough patch.
Distributions arrive quarterly, but biotech is a growth sector and payouts are a side effect, not the point.

Full GNMX profile⁠

Full IBB profile⁠

GNMX vs IBB Holdings

How GNMX and IBB differ

Overlap by weight

30.7%

Shared holdings make up 75.5% of GNMX and 32.4% of IBB.

Level by level

Sector7 Sectors0.0%
Holdings44 in both30.7%
Countryby domicile95.9%
Asset classEquity100%

Sector

Sector weights in GNMX and IBB, widest gap first
Sector	More in GNMXMore in IBB	GNMX	IBB
Health Care	GNMX +97.6 points	97.6%	0.0%
Biotechnology	IBB +87.5 points	0.0%	87.5%
Life Sciences Tools & Services	IBB +9.6 points	0.0%	9.6%
Pharmaceuticals	IBB +2.7 points	0.0%	2.7%
Technology	GNMX +2.4 points	2.4%	0.0%
Health Care Services	IBB +0.1 points	0.0%	0.1%
Health Care Equipment	IBB +0.1 points	0.0%	0.1%

Country, concentration and asset class

Country by domicile

Country weights in GNMX and IBB, widest gap first
Country	More in GNMXMore in IBB	GNMX	IBB
Denmark	GNMX +2.4 points	4.5%	2.1%
United States	IBB +1.6 points	92.7%	94.3%
United Kingdom	IBB +1.5 points	0.0%	1.5%
Switzerland	GNMX +1.0 points	1.3%	0.3%
Netherlands	GNMX +0.6 points	0.9%	0.3%
Other countries (7)	IBB +0.8 points	0.6%	1.4%

Concentration

Weight in the 10 largest Holdings

GNMX48.2%
IBB51.4%

Securities held

GNMX58
IBB241

Asset class

GNMX: Equity
IBB: Equity

Holdings

Only in GNMX14
In both44
Only in IBB197

Only in GNMX

14 securities, 24.5% of GNMX by weight

Thermo Fisher Scientific Inc8.79%
Guardant Health Inc3.66%
First American Government Obligations Fund 12/01/20312.49%
Qiagen NV2.06%
NeoGenomics Inc1.33%
Schrodinger Inc/United States1.30%
Certara Inc0.96%
Azenta Inc0.92%
GeneDx Holdings Corp0.73%
Generate Biomedicines Inc0.64%
Sophia Genetics SA0.57%
Biodesix Inc0.51%
Precision BioSciences Inc0.28%
Standard Biotools Inc0.25%

Only in IBB

197 securities, 67.5% of IBB by weight

Gilead Sciences8.94%
Amgen Inc8.31%
Regeneron Pharmaceuticals6.24%
Natera3.78%
Argenx SE Adr3.36%
Biogen2.52%
Beone Medicines AG2.11%
United Therapeutics1.68%
Insmed1.64%
Roivant Sciences Ltd1.31%
Charles River Laboratories Interna1.15%
Exelixis Inc1.13%
Ascendis Pharma1.05%
Halozyme Therapeutics1.00%
Neurocrine Biosciences1.00%
Medpace Holdings0.99%
Bridgebio Pharma0.89%
Repligen0.72%
Kymera Therapeutics0.64%
Madrigal Pharmaceuticals0.63%
Vaxcyte0.61%
Protagonist Therapeutics0.60%
Biontech SE Adr0.57%
Cytokinetics0.57%
Spyre Therapeutics Inc0.52%
Praxis Precision Medicines0.51%
Alkermes0.50%
Axsome Therapeutics0.43%
Bruker0.43%
Abivax American Depositary Shares0.43%
Rhythm Pharmaceuticals0.41%
Kodiak Sciences0.39%
Oruka Therapeutics0.39%
Cogent Biosciences0.33%
Ptc Therapeutics0.32%
Definium Therapeutics Inc0.32%
Travere Therapeutics0.31%
Mirum Pharmaceuticals0.31%
Scholar Rock Holding0.30%
Cg Oncology0.26%
Legend Biotech Adr Rep0.24%
Erasca0.24%
Arcutis Biotherapeutics0.24%
Acadia Pharmaceuticals0.24%
Tarsus Pharmaceuticals0.24%
Xenon Pharmaceuticals0.23%
Immunitybio0.22%
Edgewise Therapeutics0.22%
Tango Therapeutics0.21%
Amylyx Pharmaceuticals0.21%

Weight gaps

All 44 Holdings in both funds, largest gap first.

Holding weights in GNMX and IBB, widest gap first
Holding	More in GNMXMore in IBB	GNMX	IBB
Moderna IncMRNA	GNMX +4.18 points	9.67%	5.49%
10X Genomics IncTXG	GNMX +2.43 points	2.98%	0.55%
Genmab A/SGMAB	GNMX +2.42 points	4.56%	2.14%
CareDx IncCDNA	GNMX +2.20 points	2.48%	0.28%
GRAIL IncGRAL	GNMX +1.85 points	2.26%	0.41%
Twist Bioscience CorpTWST	GNMX +1.83 points	2.49%	0.66%
Vertex Pharmaceuticals IncVRTX	IBB +1.70 points	6.17%	7.87%
Illumina IncILMN	GNMX +1.68 points	4.09%	2.41%
Iovance Biotherapeutics IncIOVA	GNMX +1.58 points	1.81%	0.23%
Adaptive Biotechnologies CorpADPT	GNMX +1.37 points	1.65%	0.28%
Bio-Techne CorpTECH	GNMX +1.33 points	2.10%	0.77%
Tempus AI IncTEM	GNMX +1.25 points	1.78%	0.53%
BioMarin Pharmaceutical IncBMRN	GNMX +1.18 points	1.94%	0.76%
Krystal Biotech IncKRYS	GNMX +1.17 points	1.75%	0.58%
Absci CorpABSI	GNMX +1.16 points	1.27%	0.11%
Caris Life Sciences IncCAI	GNMX +1.14 points	1.44%	0.30%
Veracyte IncVCYT	GNMX +1.12 points	1.39%	0.27%
Personalis IncPSNL	GNMX +1.10 points	1.18%	0.08%
Nurix Therapeutics IncNRIX	GNMX +1.09 points	1.27%	0.18%
Incyte CorpINCY	GNMX +1.02 points	2.66%	1.64%
CRISPR Therapeutics AGCRSP	GNMX +0.96 points	1.27%	0.31%
Ideaya Biosciences IncIDYA	GNMX +0.84 points	1.04%	0.20%
uniQure NVQURE	GNMX +0.78 points	0.89%	0.11%
Relay Therapeutics IncRLAY	GNMX +0.76 points	0.97%	0.21%
Recursion Pharmaceuticals IncRXRX	GNMX +0.75 points	0.90%	0.15%
Arrowhead Pharmaceuticals IncARWR	GNMX +0.75 points	1.29%	0.54%
Castle Biosciences IncCSTL	GNMX +0.74 points	0.82%	0.08%
Beam Therapeutics IncBEAM	GNMX +0.75 points	0.92%	0.17%
Sarepta Therapeutics IncSRPT	GNMX +0.69 points	0.82%	0.13%
Pacific Biosciences of California IncPACB	GNMX +0.68 points	0.73%	0.05%
Ionis Pharmaceuticals IncIONS	GNMX +0.62 points	1.10%	0.48%
Revolution Medicines IncRVMD	GNMX +0.62 points	3.12%	2.50%
Intellia Therapeutics IncNTLA	GNMX +0.59 points	0.70%	0.11%
4D Molecular Therapeutics IncFDMT	GNMX +0.55 points	0.59%	0.04%
Myriad Genetics IncMYGN	GNMX +0.54 points	0.58%	0.04%
Prime Medicine IncPRME	GNMX +0.51 points	0.54%	0.03%
Fulgent Genetics IncFLGT	GNMX +0.49 points	0.51%	0.02%
Ultragenyx Pharmaceutical IncRARE	GNMX +0.48 points	0.58%	0.10%
Arcturus Therapeutics Holdings IncARCT	GNMX +0.40 points	0.42%	0.02%
Solid Biosciences IncSLDB	GNMX +0.37 points	0.41%	0.04%
Editas Medicine IncEDIT	GNMX +0.30 points	0.33%	0.03%
Rocket Pharmaceuticals IncRCKT	GNMX +0.25 points	0.27%	0.02%
Alnylam Pharmaceuticals IncALNY	GNMX +0.24 points	1.73%	1.49%
Caribou Biosciences IncCRBU	GNMX +0.06 points	0.06%	<0.01%

All 30 GNMX holdings⁠All 243 IBB holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

GNMX vs IBB Cost

Overpaying IBB vs GNMX

$1,726

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

GNMX 0.35%
$7,126
IBB 0.44%
$8,852

Amount$10,000

Years30 years

Cost over time

GNMX 0.35%
IBB 0.44%
Overpaying

Year by year

Year	GNMX	IBB	Overpaying
10	$634	$794	$160
20	$2,454	$3,061	$607
30	$7,126	$8,852	$1,726

Expense ratio

0.35%GNMX, cheaper
0.44%IBB

GNMX0.35%IBB0.44%

0.19%0.75%

Middle half of Biotech & Genomics funds
Median 0.47%

GNMX 3rd cheapest of 17 funds

IBB 6th cheapest of 17 funds

GNMX vs IBB Dividends

Last 12 months to Oct 30, 2026

Yield (12M): GNMX No data; IBB 0.16%
Payout (12M): GNMX None; IBB $0.34
Last payment: GNMX No data; IBB $0.01
Ex-dividend: GNMX No data; IBB Sep 15, 2026
Paid on: GNMX No data; IBB Sep 18, 2026
Frequency: GNMX No data; IBB Quarterly

Distribution history

Per share, 2017 to 2026, same scale for both

GNMXAll GNMX payments⁠

No distribution history available.

IBBQuarterly · 36 paymentsAll IBB payments⁠

GNMX vs IBB Risk

Fall from peak · 5 years

This chart needs five years of history for both funds.

Risk facts

VolatilityStd dev, 3 years: GNMX No dataIBB 17.9%
Return per unit of riskSharpe ratio, 3 years: GNMX No dataIBB 1.07
Worst fallMax drawdown, 5 years: GNMX No dataIBB −35.7%
Market sensitivityBeta, 5 years: GNMX 2.27IBB 0.70; Market = 1

GNMX and IBB in the news

All news⁠

Deep Dive
Moderna fell 18% on cancer-vaccine data, and genomics ETFs fell 4%
Oct 23, 2026IBB
News
AstraZeneca agrees to invest $2 billion in Summit, without the drug rights
Sep 28, 2026IBB
Deep Dive
Health care's 1.8% week was four large caps, not a biotech rally
Sep 19, 2026IBB
Deep Dive
Health care ETFs spent 2026 between a 28% biotech rally and a 16% device slide
Sep 14, 2026IBB

Popular comparisons

GNMXCvsXBIA
Corgi Genomics & Precision Medicine ETF · State Street SPDR S&P Biotech ETF
Expense ratio
0.35% · 0.35%
Category
IBBAvsXBIA
iShares Biotechnology ETF · State Street SPDR S&P Biotech ETF
Expense ratio
0.44% · 0.35%
Category
GNMXCvsIBBQA
Corgi Genomics & Precision Medicine ETF · Invesco Nasdaq Biotechnology ETF
Expense ratio
0.35% · 0.19%
Category
IBBAvsIBBQA
iShares Biotechnology ETF · Invesco Nasdaq Biotechnology ETF
Expense ratio
0.44% · 0.19%
Category
GNMXCvsBBPA
Corgi Genomics & Precision Medicine ETF · Virtus Biotech ETF
Expense ratio
0.35% · 0.34%
Category
IBBAvsBBPA
iShares Biotechnology ETF · Virtus Biotech ETF
Expense ratio
0.44% · 0.34%
Category

GNMX vs IBB

In short

Stated mandate

Why people hold it